Well differentiated papillary mesothelial tumor: a new name and new problems

Andrew Churg1, Francoise Galateau-Salle2

  • 1Department of Pathology, Vancouver General Hospital, Vancouver, BC, Canada. achurg@mail.ubc.ca.

Insights

Well-differentiated papillary mesothelial tumor (WDPMT) may be distinct from invasive mesothelioma. Distinguishing WDPMT from papillary mesothelioma in situ is crucial, necessitating specific diagnostic tests like BAP1 immunostaining.

Area of Science:

  • Oncology
  • Pathology
  • Genetics

Background:

  • Well-differentiated papillary mesothelial tumor (WDPMT) is a distinct lesion.
  • Its relationship to invasive mesothelioma is uncertain.
  • Genetic profiles of WDPMT differ from invasive mesotheliomas.

Purpose of the Study:

  • To differentiate true WDPMT from morphologically similar lesions.
  • To clarify the precursor role of WDPMT in invasive mesothelioma.
  • To establish diagnostic criteria for distinguishing these entities.

Main Methods:

  • Morphological analysis of mesothelial lesions.
  • Genetic analysis (mutations, copy number losses) of WDPMT.
  • Immunohistochemical staining (BAP1) and FISH (MTAP, CDKN2A) for diagnostic distinction.

Main Results:

  • WDPMT shows distinct genetic alterations compared to invasive mesotheliomas.
  • Papillary mesothelioma in situ can mimic WDPMT morphologically.
  • BAP1 loss is a key feature in distinguishing these lesions.

Conclusions:

  • WDPMT is likely a benign process, separate from invasive mesothelioma.
  • Papillary mesothelioma in situ can present with WDPMT morphology.
  • Diagnostic immunostaining for BAP1 and potentially FISH for MTAP/CDKN2A are essential for accurate diagnosis.